Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 41c, Revenues Miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $78.89 -0.48%
Revenue Growth %: +89.8%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +89.8%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of $0.13, $0.41 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $34.66 million versus the consensus estimate of $71.6 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Investing.com’s stocks of the week
- Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
